Quantitative NMR analysis of Erk activity and inhibition by U0126 in a panel of patient-derived colorectal cancer cell lines

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1834, Issue 7, 2013, Pages 1396-1401

  Rose, Honor May ^a   Stuiver, Marchel ^a   Thongwichian, Rossukon ^a   Theillet, Francois Xavier ^a   Feller, Stephan M ^b   Selenko, Philipp ^a  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Colorectal cancer cell; Erk1 2; High resolution NMR spectroscopy; MAPK; Protein phosphorylation; U0126

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UO 126;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

BIOCATALYSIS; BLOTTING, WESTERN; BUTADIENES; CELL LINE, TUMOR; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PHOSPHORYLATION; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84878861600     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.01.023     Document Type: Article

References (41)

1. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, and A. Tafuri Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim. Biophys. Acta 1773 2007 1263 1284 (Pubitemid 47125967)
2. J.S. Sebolt-Leopold Development of anticancer drugs targeting the MAP kinase pathway Oncogene 19 2000 6594 6599 (Pubitemid 32197697)
3. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297 (Pubitemid 39551656)
4. J.J. Hoozemans, R. Hilhorst, R. Ruijtenbeek, A.J. Rozemuller, and S.M. van der Vies Protein kinase activity profiling of postmortem human brain tissue Neurodegener. Dis. 10 2012 46 48
5. D.J. Bernsteel, D.L. Roman, and R.R. Neubig In vitro protein kinase activity measurement by flow cytometry Anal. Biochem. 383 2008 180 185
6. R. Hilhorst, L. Houkes, A. van den Berg, and R. Ruijtenbeek Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A Anal. Biochem. 387 2009 150 161
7. S.A. Singh, D. Winter, P.M. Bilimoria, A. Bonni, H. Steen, and J.A. Steen FLEXIQinase, a mass spectrometry-based assay, to unveil multikinase mechanisms Nat. Methods 9 2012 504 508
8. K. Kubota, R. Anjum, Y. Yu, R.C. Kunz, J.N. Andersen, M. Kraus, H. Keilhack, K. Nagashima, S. Krauss, and C. Paweletz Sensitive multiplexed analysis of kinase activities and activity-based kinase identification Nat. Biotechnol. 27 2009 933 940
9. J.C. Gingrich, D.R. Davis, and Q. Nguyen Multiplex detection and quantitation of proteins on western blots using fluorescent probes Biotechniques 29 2000 636 642
10. S. Deswal, A.K. Schulze, T. Hofer, and W.W. Schamel Quantitative analysis of protein phosphorylations and interactions by multi-colour IP-FCM as an input for kinetic modelling of signalling networks PLoS One 6 2011 e22928
11. A. Cappione III, J. Smith, M. Mabuchi, and T. Nadler Rapid screening of the epidermal growth factor receptor phosphosignaling pathway via microplate-based dot blot assays Int. J. Proteomics 2012 2012 473843
12. C.Y. Huang, and J.E. Ferrell Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade Proc. Natl. Acad. Sci. U. S. A. 93 1996 10078 10083 (Pubitemid 26314577)
13. A. Fujioka, K. Terai, R.E. Itoh, K. Aoki, T. Nakamura, S. Kuroda, E. Nishida, and M. Matsuda Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes J. Biol. Chem. 281 2006 8917 8926 (Pubitemid 43847999)
14. P. Selenko, D.P. Frueh, S.J. Elsaesser, W. Haas, S.P. Gygi, and G. Wagner In situ observation of protein phosphorylation by high-resolution NMR spectroscopy Nat. Struct. Mol. Biol. 15 2008 321 329 (Pubitemid 351654049)
15. F.X. Theillet, C. Smet-Nocca, S. Liokatis, R. Thongwichian, J. Kosten, M.K. Yoon, R.W. Kriwacki, I. Landrieu, G. Lippens, and P. Selenko Cell signaling, post-translational protein modifications and NMR spectroscopy J. Biomol. NMR 54 2012 217 236
16. T. Sakai, H. Tochio, T. Tenno, Y. Ito, T. Kokubo, H. Hiroaki, and M. Shirakawa In-cell NMR spectroscopy of proteins inside Xenopus laevis oocytes J. Biomol. NMR 36 2006 179 188 (Pubitemid 44740881)
17. G. Lippens, I. Landrieu, and X. Hanoulle Studying posttranslational modifications by in-cell NMR Chem. Biol. 15 2008 311 312 (Pubitemid 351508430)
18. S. Liokatis, A. Dose, D. Schwarzer, and P. Selenko Simultaneous detection of protein phosphorylation and acetylation by high-resolution NMR spectroscopy J. Am. Chem. Soc. 132 2010 14704 14705
19. T.R. Kress, T. Raabe, and S.M. Feller High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells Cell Commun. Signal. 8 2010 1
20. R.J. Santen, R.X. Song, R. McPherson, R. Kumar, L. Adam, M.H. Jeng, and W. Yue The role of mitogen-activated protein (MAP) kinase in breast cancer J. Steroid Biochem. Mol. Biol. 80 2002 239 256 (Pubitemid 34233743)
21. M.R. Junttila, S.P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J. 22 2008 954 965 (Pubitemid 351519953)
22. A.S. Dhillon, S. Hagan, O. Rath, and W. Kolch MAP kinase signalling pathways in cancer Oncogene 26 2007 3279 3290 (Pubitemid 46763021)
23. M. Schilling, T. Maiwald, S. Hengl, D. Winter, C. Kreutz, W. Kolch, W.D. Lehmann, J. Timmer, and U. Klingmuller Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions Mol. Syst. Biol. 5 2009 334
24. G. Rodriguez-Berriguete, B. Fraile, P. Martinez-Onsurbe, G. Olmedilla, R. Paniagua, and M. Royuela MAP kinases and prostate cancer J. Signal Transduct. 2012 2012 169170
25. E.K. Kim, and E.J. Choi Pathological roles of MAPK signaling pathways in human diseases Biochim. Biophys. Acta 1802 2010 396 405
26. G. Werlen, B. Hausmann, D. Naeher, and E. Palmer Signaling life and death in the thymus: timing is everything Science 299 2003 1859 1863 (Pubitemid 36356648)
27. R. Treisman Ternary complex factors: growth factor regulated transcriptional activators Curr. Opin. Genet. Dev. 4 1994 96 101 (Pubitemid 24060302)
28. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, and I. Osman BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362 (Pubitemid 43128863)
29. J.J. Yeh, E.D. Routh, T. Rubinas, J. Peacock, T.D. Martin, X.J. Shen, R.S. Sandler, H.J. Kim, T.O. Keku, and C.J. Der KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Mol. Cancer Ther. 8 2009 834 843
30. M.F. Favata, K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, and F. Hobbs Identification of a novel inhibitor of mitogen-activated protein kinase kinase J. Biol. Chem. 273 1998 18623 18632 (Pubitemid 28334795)
31. P.L. Rice, R.J. Goldberg, E.C. Ray, L.J. Driggers, and D.J. Ahnen Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites Cancer Res. 61 2001 1541 1547 (Pubitemid 34292585)
32. A. Alegria-Schaffer, A. Lodge, and K. Vattem Performing and optimizing Western blots with an emphasis on chemiluminescent detection Methods Enzymol. 463 2009 573 599
33. D.L. Sheridan, Y. Kong, S.A. Parker, K.N. Dalby, and B.E. Turk Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs J. Biol. Chem. 283 2008 19511 19520
34. A. Dose, S. Liokatis, F.X. Theillet, P. Selenko, and D. Schwarzer NMR profiling of histone deacetylase and acetyl-transferase activities in real time ACS Chem. Biol. 6 2011 419 424
35. P. Schanda, E. Kupce, and B. Brutscher SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds J. Biomol. NMR 33 2005 199 211 (Pubitemid 43118574)
36. S. Procaccia, S. Kraus, and R. Seger Determination of ERK activity: anti-phospho-ERK antibodies and in vitro phosphorylation Methods Mol. Biol. 661 2010 39 58
37. G. Pohl, C.L. Ho, R.J. Kurman, R. Bristow, T.L. Wang, and IeM Shih Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Res. 65 2005 1994 2000 (Pubitemid 40478629)
38. B.R. Davies, A. Logie, J.S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P.D. Smith AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models Mol. Cancer Ther. 6 2007 2209 2219 (Pubitemid 47294749)
39. Y. Wang, K. Van Becelaere, P. Jiang, S. Przybranowski, C. Omer, and J. Sebolt-Leopold A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040 Neoplasia 7 2005 336 347 (Pubitemid 40664223)
40. W.J. van Houdt, M.T. de Bruijn, B.L. Emmink, D. Raats, F.J. Hoogwater, I.H. Borel Rinkes, and O. Kranenburg Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition Cell. Oncol. 32 2010 245 257
41. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315